In the past week, AVTX stock has gone down by -7.14%, with a monthly decline of -36.36% and a quarterly plunge of -24.17%. The volatility ratio for the week is 12.06%, and the volatility levels for the last 30 days are 11.51% for Avalo Therapeutics Inc The simple moving average for the last 20 days is -12.77% for AVTX stock, with a simple moving average of -93.95% for the last 200 days.

Is It Worth Investing in Avalo Therapeutics Inc (NASDAQ: AVTX) Right Now?

Additionally, the 36-month beta value for AVTX is 1.17. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price predicted by analysts for AVTX is $0.75, which is $0.66 above the current price. The public float for AVTX is 190.90M and currently, short sellers hold a 6.74% ratio of that float. The average trading volume of AVTX on November 16, 2023 was 74.80M shares.

AVTX) stock’s latest price update

The stock of Avalo Therapeutics Inc (NASDAQ: AVTX) has decreased by -7.89 when compared to last closing price of 0.10. Despite this, the company has experienced a -7.14% fall in its stock price over the last five trading sessions. Invezz reported 2023-10-12 that Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer’s acquisition of Seagen, Eli Lilly’s buyout of POINT Biopharma and Versanis Bio, and Roche’s purchase of Good Therapeutics.

Analysts’ Opinion of AVTX

Many brokerage firms have already submitted their reports for AVTX stocks, with RBC Capital Mkts repeating the rating for AVTX by listing it as a “Outperform.” The predicted price for AVTX in the upcoming period, according to RBC Capital Mkts is $6 based on the research report published on September 24, 2021 of the previous year 2021.

AVTX Trading at -27.56% from the 50-Day Moving Average

After a stumble in the market that brought AVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.50% of loss for the given period.

Volatility was left at 11.51%, however, over the last 30 days, the volatility rate increased by 12.06%, as shares sank -24.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.11% lower at present.

During the last 5 trading sessions, AVTX fell by -3.37%, which changed the moving average for the period of 200-days by -97.57% in comparison to the 20-day moving average, which settled at $0.1028. In addition, Avalo Therapeutics Inc saw -98.19% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at AVTX starting from ARMISTICE CAPITAL, LLC, who sale 937,404 shares at the price of $0.52 back on Jun 27. After this action, ARMISTICE CAPITAL, LLC now owns 731,458 shares of Avalo Therapeutics Inc, valued at $486,888 using the latest closing price.

ARMISTICE CAPITAL, LLC, the 10% Owner of Avalo Therapeutics Inc, sale 2,746,138 shares at $0.61 during a trade that took place back on Jun 26, which means that ARMISTICE CAPITAL, LLC is holding 1,668,862 shares at $1,682,010 based on the most recent closing price.

Stock Fundamentals for AVTX

Current profitability levels for the company are sitting at:

The net margin for Avalo Therapeutics Inc stands at -230.78. The total capital return value is set at -102.35, while invested capital returns managed to touch -125.83. Equity return is now at value -524.01, with -100.85 for asset returns.

When we switch over and look at the enterprise to sales, we see a ratio of 13.10, with the company’s debt to enterprise value settled at 0.41. The receivables turnover for the company is 5.37 and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.


In conclusion, Avalo Therapeutics Inc (AVTX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..